Trial Profile
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Sep 2023
Price :
$35
*
At a glance
- Drugs Ropinirole (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 27 Apr 2012 Actual patient number of the extension trial (NCT01536574) is 295 as reported by ClinicalTrials.gov.
- 14 Oct 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
- 14 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.